CardioTech and Credent form deal on ChronoFlex RC
This article was originally published in Clinica
CardioTech International has granted an exclusive worldwide licence of its IP rights for its ChronoFlex RC technology to UK company Credent Vascular Technologies, which will now be able to exclusively synthesise ChronoFlex RC biodurable polycarbonate-urethane, for the manufacture of vascular access and peripheral access grafts.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.
An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.